188057-44-5

Basic information

• Product Name: (1R,3S,4S)-3-formyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester
• Synonyms: (1R,3S,4S)-3-formyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester
• CAS NO: 188057-44-5
• Molecular Weight: 225.288
• Mol File: 188057-44-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (1R,3S,4S)-3-formyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,3S,4S)-3-formyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester(188057-44-5)
• EPA Substance Registry System: (1R,3S,4S)-3-formyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester(188057-44-5)

Safety Data

• Hazardous Substances Data: 188057-44-5(Hazardous Substances Data)

Upstream product

• 130194-96-6 (1S,3S,4R)-2-[(1R)-1-phenylethyl]-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid methyl ester 
• 1181573-36-3 (1R,3S,4S)-2-azabicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester 
• 188057-43-4 tert-butyl (1R,3S,4S)-3-(hydroxymethyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 542-92-7 cyclopenta-1,3-diene 
• 764622-98-2 (1S,3S,4R)-2-Aza-bicyclo[2.2.1]hept-5-ene-3-carboxylic acid ethyl ester 
• 214910-41-5 (1R,3S,4S)-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid ethyl ester 
• 188057-42-3 ethyl (1R,3S,4S)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptane-3-carboxylate 
• 134795-25-8 (1R,3S,4S)-2-aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 

Downstream Products

• 1181573-40-9 (1R,3S,4S)-3-(benzylamino-methyl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 

Relevant articles and documents

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.